Prognostic significance of mean platelet volume in patients with lung cancer: a meta-analysis

Kharel, Sanjeev; Shrestha, Suraj; Shakya, Prafulla; Rawat, Rohit; Shilpakar, Ramila

doi:10.1177/03000605221084874

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More particularly, most studies in colon cancer (4 out of 6) and fewer in lung cancer (4 out of 10) indicated an unfavorable role of increased MPV regarding mortality. It is noted that MPV was not related to overall survival in a recent meta-analysis of lung cancer patients [ 26 ]. As far as other cancer types are concerned, fewer studies were conducted.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, there are few reviews on the relationship between MPV and cancer; including studies up to 2015, Ref. [ 24 ] is a recent review that has evaluated platelet indices with esophageal squamous cell carcinoma [ 25 ], and it includes a meta-analysis of 2421 patients, which has focused on the relation of MPV to survival in lung cancer patients [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relation of Mean Platelet Volume (MPV) with Cancer: A Systematic Review with a Focus on Disease Outcome on Twelve Types of Cancer

et al. 2023

View full text Add to dashboard Cite

Inflammatory proteins activate platelets, which have been observed to be directly related to cancer progression and development. The aim of this systematic review is to investigate the possible association between Mean Platelet Volume (MPV) and cancer (diagnostic capacity of MPV, relation to survival, the severity of the disease, and metastasis). A literature review was performed in the online database PubMed and Google Scholar for the period of 2010–2022. In total, 83 studies including 21,034 participants with 12 different types of cancer (i.e., gastric cancer, colon cancer, esophageal squamous cell carcinoma, renal cancer, breast cancer, ovarian cancer, endometrial cancer, thyroid cancer, lung cancer, bladder cancer, gallbladder cancer, and multiple myeloma) were identified. The role of MPV has been extensively investigated in several types of cancer, such as gastric, colon, breast, and lung cancer, while few data exist for other types, such as renal, gallbladder cancer, and multiple myeloma. Most studies in gastric, breast, endometrium, thyroid, and lung cancer documented an elevated MPV in cancer patients. Data were less clear-cut for esophageal, ovarian, and colon cancer, while reduced MPV was observed in renal cell carcinoma and gallbladder cancer. Several studies on colon cancer (4 out of 6) and fewer on lung cancer (4 out of 10) indicated an unfavorable role of increased MPV regarding mortality. As far as other cancer types are concerned, fewer studies were conducted. MPV can be used as a potential biomarker in cancer diagnosis and could be a useful tool for the optimization of treatment strategies. Possible underlying mechanisms between cancer and MPV are discussed. However, further studies are needed to elucidate the exact role of MPV in cancer progression and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Relation of Mean Platelet Volume (MPV) with Cancer: A Systematic Review with a Focus on Disease Outcome on Twelve Types of Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For instance, a study of 496 NSCLC patients at stages IIIB/IV showed that a high level of MPV is associated with shorter OS (Omar et al 2018 ). On the other hand, a recent meta-analysis of 2,421 patients with NSCLC from 11 publications revealed no significant associations of MPV with OS and PFS (Kharel et al 2022 ). It must be, however, noted that none of the included studies was prospective, and that the meta-analysis did not specify differences between different types of treatment.…”

Section: Discussionmentioning

confidence: 99%

Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors

Krizova,

Benesova,

Zemanova

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of patients with NSCLC. Unfortunately, a reliable predictive biomarker is still missing. Commonly used biomarkers, such as PD-L1, MSI, or TMB, are not quite accurate in predicting ICI efficacy. Methods In this prospective observational cohort study, we investigated the predictive role of erythrocytes, thrombocytes, innate and adaptive immune cells, complement proteins (C3, C4), and cytokines from peripheral blood of 224 patients with stage III/IV NSCLC treated with ICI alone (pembrolizumab, nivolumab, and atezolizumab) or in combination (nivolumab + ipilimumab) with chemotherapy. These values were analyzed for associations with the response to the treatment and survival endpoints. Results Higher baseline Tregs, MPV, hemoglobin, and lower monocyte levels were associated with favorable PFS and OS. Moreover, increased baseline basophils and lower levels of C3 predicted significantly improved PFS. The levels of the baseline immature granulocytes, C3, and monocytes were significantly associated with the occurrence of partial regression at the first restaging. Multiple studied parameters (n = 9) were related to PFS benefit at the time of first restaging as compared to baseline values. In addition, PFS nonbenefit group showed a decrease in lymphocyte count after three months of therapy. The OS benefit was associated with higher levels of lymphocytes, erythrocytes, hemoglobin, MCV, and MPV, and a lower value of NLR after three months of treatment. Conclusion Our work suggests that parameters from peripheral venous blood may be potential biomarkers in NSCLC patients on ICI. The baseline values of Tregs, C3, monocytes, and MPV are especially recommended for further investigation.

show abstract

“…Reports of poor prognosis for lower MPV measured at diagnosis [ 31 , 32 ] may be more relevant to our findings because these are based on prospective studies and reflect lung cancer progression, which may involve pathways relevant to lung cancer development. Cancer survival, however, is dependent on comorbidities related to platelet activity, as well as on cancer progression and metastasis, and a large meta-analysis has found little evidence for association of MPV measured at diagnosis with overall survival [ 33 ]. Our findings are compatible with a small scale study reporting higher PDW at lung cancer diagnosis [ 15 ], but only for men.…”

Section: Discussionmentioning

confidence: 99%

Interactions of platelets with obesity in relation to lung cancer risk in the UK Biobank cohort

Christakoudi,

Tsilidis,

Evangelou

et al. 2023

Respir Res

View full text Add to dashboard Cite

Background Platelet count (PLT) is associated positively with lung cancer risk but has a more complex association with body mass index (BMI), positive only in women (mainly never smokers) and inverse in men (mainly ever smokers), raising the question whether platelets interact with obesity in relation to lung cancer risk. Prospective associations of platelet size (an index of platelet maturity and activity) with lung cancer risk are unclear. Methods We examined the associations of PLT, mean platelet volume (MPV), and platelet distribution width (PDW) (each individually, per one standard deviation increase) with lung cancer risk in UK Biobank men and women using multivariable Cox proportional hazards models adjusted for BMI and covariates. We calculated Relative Excess Risk from Interaction (RERI) with obese (BMI ≥ 30 kg/m2), dichotomising platelet parameters at ≥ median (sex-specific), and multiplicative interactions with BMI (continuous scale). We examined heterogeneity according to smoking status (never, former, current smoker) and antiaggregant/anticoagulant use (no/yes). Results During a mean follow-up of 10.4 years, 1620 lung cancers were ascertained in 192,355 men and 1495 lung cancers in 218,761 women. PLT was associated positively with lung cancer risk in men (hazard ratio HR = 1.14; 95% confidence interval (CI): 1.09–1.20) and women (HR = 1.09; 95%CI: 1.03–1.15) but interacted inversely with BMI only in men (RERI = − 0.53; 95%CI: − 0.80 to − 0.26 for high-PLT-obese; HR = 0.92; 95%CI = 0.88–0.96 for PLT*BMI). Only in men, MPV was associated inversely with lung cancer risk (HR = 0.95; 95%CI: 0.90–0.99) and interacted positively with BMI (RERI = 0.27; 95%CI = 0.09–0.45 for high-MPV-obese; HR = 1.08; 95%CI = 1.04–1.13 for MPV*BMI), while PDW was associated positively (HR = 1.05; 95%CI: 1.00–1.10), with no evidence for interactions. The associations with PLT were consistent by smoking status, but MPV was associated inversely only in current smokers and PDW positively only in never/former smokers. The interactions with BMI were retained for at least eight years of follow-up and were consistent by smoking status but were attenuated in antiaggregant/anticoagulant users. Conclusions In men, PLT was associated positively and MPV inversely with lung cancer risk and these associations appeared hindered by obesity. In women, only PLT was associated positively, with little evidence for interaction with obesity.

show abstract

Prognostic significance of mean platelet volume in patients with lung cancer: a meta-analysis

Cited by 4 publications

References 40 publications

Relation of Mean Platelet Volume (MPV) with Cancer: A Systematic Review with a Focus on Disease Outcome on Twelve Types of Cancer

Relation of Mean Platelet Volume (MPV) with Cancer: A Systematic Review with a Focus on Disease Outcome on Twelve Types of Cancer

Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors

Interactions of platelets with obesity in relation to lung cancer risk in the UK Biobank cohort

Contact Info

Product

Resources

About